trial with title TRANSCEND - Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) - TRANSCEND-CLL-004 - US

*Study enrollment impact due to Coronavirus (COVID-19)*

Please note that some study locations are now accepting new study participants, however some locations remain closed due to the ongoing impact of Coronavirus (COVID-19). Please continue to check back as we expect to add more study locations as this situation improves and changes.

Who is eligible to participate?

TRANSCEND CLL 004 may be an option for those who meet the following criteria:

  • Are 18 years of age and older
  • Have been diagnosed with CLL or SLL
  • Have CLL/SLL that has relapsed (your disease has come back) or refractory (your disease has not responded)

Please note that travel reimbursement may be available as an option so please discuss this with the study site in question. For study site location information, click here to visit

Online pre-screener:

If you meet the initial criteria above, please take the prescreening questionnaire below to see if you might qualify to participate in this study. If you pass the pre-screener you will have the opportunity to search and provide your contact information to a study site so that you can discuss the study with the study site and arrange for a screening visit, if applicable.

Check if you are eligible Enter contact details Select a site

Have you been diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)?

For more information, please watch the video.

Participation in the study lasts approximately 26 months. This includes:

  • A pretreatment period that will occur seven days before the treatment period. During this time, the study doctor will confirm if you are eligible for treatment. If you are eligible, baseline measurements will be taken.
  • A treatment period that will last up to 30 days. The treatment is a one-day infusion, with a concentrated follow-up period in the first 30 days.
  • A follow-up period when you will visit the study site at least eight times before your participation in the study ends. This period will last two years.

The investigational study drug used in TRANSCEND CLL 004 is called JCAR017. This drug is the result of a modification to a participant’s own immune cells (T cells) with a chimeric antigen receptor (CAR). These modified T cells (CAR T cells), may target and reduce the number of cancer cells, which then could provide an environment for healthy cells to grow normally.  JCAR017 is administered once as an infusion during the treatment period.